Eli Lilly on Wednesday forecast 2018 earnings and revenue largely above analysts’ estimates in part due to strong demand for recently launched diabetes drug Trulicity and psoriasis drug Taltz.

The company said it expected 2018 revenue of $ 23.0 billion to $ 23.5 billion and adjusted earnings of $ 4.60 to $ 4.70 per share.

Analysts on average were expecting revenue of $ 23.07 billion and earnings of …
Health Care